CureVac (CVAC) announced that Myriam Mendila has taken up her role as CureVac’s Chief Development Officer, as previously announced. Over the last 5 years, she has held the position of Chief Medical Officer Oncology and Global Head of Oncology Medical Affairs at Novartis, being responsible for the Medical Affairs strategy and related activities across the overall oncology portfolio at Novartis (NVS).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CVAC:
- JMP Securities says older-adult update continues to look encouraging for CureVac
- CureVac announces data in older adults from COVID-19, flu mRNA vaccines
- Street Wrap: Today’s Top 15 Upgrades, Downgrades, Initiations
- CVAC Jumps After Analyst Upgrade
- UBS upgrades CureVac after ‘major milestone and clearing event’